Cambridge UK, 11 December 2019: Abcam has been honoured with a Glassdoor Employees’ Choice Award, recognising the Best Places to Work in 2020. Abcam is ranked 6th in Glassdoor’s Best Places to Work UK list.
The Employees’ Choice Awards are based solely on the input of employees who elect to provide feedback on their jobs, work environments and companies on Glassdoor, one of the world’s largest job and recruiting sites.
Alan Hirzel, CEO, Abcam, commented “I’m delighted that our people have rated Abcam as one of the best places to work. As we continue to grow, we want to attract and retain the…
Events showcasing the latest products and innovations for lab professionals spans seven countries
LOUGHBOROUGH, England (Dec. 9, 2019) – Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 29 customer sites in 2019.Emily Quinton, European Marketing Communications Manager, commented: “Activate Science has touched nearly 2,500 delegates stretching over seven European countries this year and provides a valuable opportunity to network and experience the latest innovations in laboratory products…
Cambridge, UK, December 10 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has joined the EU-funded Exposome Project for Health and Occupational Research (EPHOR). The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes into account all occupational and related non-occupational exposures (e.g. lifestyle) throughout the lifespan of an individual. Owlstone Medical will receive funding…
AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.Oligodendrocyte cells in the central nervous system can contact up to 50 axon segments per cell to form such myelin sheaths. Meng-Meng Fu of Stanford University and co-authors cultured oligodendrocytes in 3D in vitro on Mimetix® aligned 3D…
ScreenIn3D, a partner of AMSBIO, has been awarded the prestigious ELRIG Prize for Innovation in Drug Discovery at their flagship conference Drug Discovery 2019 which recently took place in Liverpool, UK.ELRIG Drug Discovery has become the largest meeting of life sciences industry professionals in the UK. The 2-day event brings together more than 1200 delegates and over 100 exhibiting companies from around the world to highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel…
Cambridge, UK and Moscow, Russia, 09 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical company, focused on developing and commercialising pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia (ALL). This is the first IBC Generium…
Cambridge, UK, 09 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex,…
Westbury, NY – Dec. 9, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a drug discovery webinar that will discuss how small interfering RNA (siRNA) molecules can be used to selectively suppress hepatic genes in an in vitro liver model and advance the development of small molecule and nucleic acid therapies.
BioIVT’s HEPATOPAC® Technology is used to form a micro-patterned co-culture of primary hepatocytes and non-parenchymal stromal cells which maintain in vivo-like liver function and metabolic activity…
Cambridge, UK - 9 December 2019 - Healx the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
The project will leverage Healx’s comprehensive AI-based drug discovery platform, Healnet, and expertise in rare diseases and pharmacology, to identify potential new indications for assets from Boehringer Ingelheim’s pipeline.
Healx will use their data analysis and technological capabilities to assist Boehringer…
Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin
Favourable pharmacokinetic/pharmacodynamic profile compared to current best in class insulin treatment
Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247. In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.…